Biotech MedPartners


  •  Valuation in Portfolio Management
  • Major developments in the Biopharma industry
  • Bring the best science to neglected patients
  • Are you ready for JP Morgan 2017?
  • Share your lab!
  • Look at Celldex
  • Google will diagnose cancers
  • 10 steps to a successful fundraising campaign
  • Bristol trades like a biotech
  • One more antisense therapy with huge potential...Morgensen!
  • Beyond anti-TNF-α agents in inflammation...   
  • Talent acquisition is Strategic...
  • Correction or not?
  • Pharma World Preview 2014, Outlook to 2020
  • Have a look at free report on drug trend
  • A BIG Man.
  • Mass Biotech !
  • Top 25 Molecular Millionaires What do they have in common?
  • The 20th annual BIO-Europe® interesting opportunity to grab EU biotechs for a good price
  • Everything is about finding the right model...
  • Roche demonstrates agility at the front-end of the innovation process
  • Biosimilars set to boom as new patent cliff on biologic superstars looms
  • Excellent news for MEK inhibitors
  • Skyrocketing Q2 for Biotech
  • Do you really want to be a biotech board member?
  • One more deal in the checkpoint inhibitors arena...
  • Biotech bull market charges with Merck’s Idenix takeout
  • Attractive Indian deals 
  • More than 900 drugs are in development in oncology!
  • China, the new "Singapore"
  • The "cloud" business model in biotech...

Global Offices




  • ASCO 2014 - what are the big stars?
  • Don't throw out planning, budgeting and forecasting...Before to complete a solid competitive analysis using professionals who know what they are talking about.
  • The 10 most highly-valued life science companies in Mass., and how many employees they have
  • Pharmaceutical and Life Sciences Deals Insights
  • You should review your forecasts!
  • What Lies Ahead for 2014?
  • Amgen beats a path to the FDA, looking for an early approval of leukemia drug
  • Is the current biotech boom sustainable?
  • Top 10 Drugs of 2014?
  • Get ready for an innovative and forward-thinking partnership
  • Future of Cancer treatment
  • Let's Dance Together...Funky Biotech!
  • PD-L1 the new race for the checkpoint
  • Our predictions for 2014 come true!
  • ATB is HOT
  • Where to Search for Funding and Grants?
  • Interested in IPO Investing?
  • Biotech Investing Strategies in 2014
  • $3bn for Xofigo!
  • B.I.G thinking for 2014: "Look beyond the pill"
  • R&D cost Is There No End To The Biotech Bull Market?
  • 10 biotech developments from the World Economic Forum
  • Amgen to buy a portfolio in cancer...
  • I wish you to be a biotech innovator
  • 5 Pharmas With Phase III Clinical Study Catalysts
  • An Insider’s View on Raising Money from Life Sciences VCs
  • Euro-Biotech Partnering Summit 2012 in Paris!
  • The day a drug company boss saw the light Again! 
  • Is there any good lesson VCs should learn here now?
  • Patent proof of rising innovation..."the beginning of everything"
  • FP7 €650m in grants for 2012
  • The "friendly" battle
  • Partner for genetically modified seeds
  • Finally even Eli Lilly is taking a new approach to R&D
  • Navigating Earn-Outs and Contingent Value Rights (CVRs) for BioTech Acquisitions: Strategies for Success
  • Biotech VC investing grows 3% in 2010 




The battle of the checkpoint inhibitors

In order to create long-term value and competitive advantage, our clients must constantly prepare for an evolving industry.
Biotech MedPartners’ pure life sciences focus, unique analysis capabilities and global perspective enables us to spot trends and emerging issues quickly and help clients break barriers, develop new and sustainable solutions, and create, transformational impact.